Table 1: Cohort Characteristics.
Characteristics of the 5,786 MESA participants stratified by sex and angiotensinogen (below median versus above sex-specific median). Median angiotensinogen was 18.3 μg/mL in males and 22.4 μg/mL in females.
| Male (N = 2776) | Female (N = 3010) | |||
|---|---|---|---|---|
| Characteristic | Below Median | Above Median | Below Median | Above Median |
|
| ||||
| Mean age ± SD, years | 63.4 ± 10.0 | 61.7 ± 10.3 | 63.2 ± 10.7 | 62.2 ± 9.8 |
| Race/Ethnicity, n (%) | ||||
| White | 484 (46.1) | 565 (53.9) | 439 (39.7) | 666 (60.3) |
| Chinese | 216 (61.5) | 135 (38.5) | 226 (63.8) | 128 (36.2) |
| Black | 378 (49.6) | 384 (50.4) | 480 (53.1) | 424 (46.9) |
| Hispanic | 325 (52.9) | 289 (47.1) | 363 (56.1) | 284 (43.9) |
| Post-Menopause | 1234 (49.3) | 1268 (50.7) | ||
| Diabetes, n (%) | 201 (50.6) | 196 (49.4) | 189 (55.1) | 154 (44.9) |
| Mean BMI ± SD, kg/m2 | 27.7 ± 4.5 | 28.0 ± 4.4 | 28.9 ± 6.3 | 28.7 ± 6.1 |
| Mean total cholesterol ± SD, mg/dL | 182.3 ± 32.7 | 193.7 ± 36.5 | 196.3 ± 34.7 | 202.9 ± 36.1 |
| Mean HDL cholesterol ± SD, mg/dL | 44.6 ± 11.5 | 45.6 ± 12.0 | 54.0 ± 14.4 | 58.6 ± 16.1 |
| Mean LDL cholesterol ± SD, mg/dL | 113.5 ± 29.9 | 119.4 ± 32.0 | 119.2 ± 31.3 | 116.4 ± 32.5 |
| Mean systolic BP ± SD, mmHg | 125.6 ± 19.8 | 126.7 ± 19.0 | 128.0 ± 23.8 | 127.6 ± 22.6 |
| Mean diastolic BP ± SD, mmHg | 74.5 ± 9.3 | 75.7 ± 9.5 | 69.2 ± 10.4 | 69.1 ± 9.9 |
| Median hs-CRP (Q1, Q3), mg/L | 1.230 [0.640, 2.780] | 1.590 [0.780, 3.360] | 1.940 [0.860, 4.200] | 3.230 [1.420, 6.907] |
| Creatinine, mg/dL | 1.02 [0.92, 1.12] | 1.02 [0.92, 1.22] | 0.82 [0.72, 0.92] | 0.82 [0.72, 0.92] |
| eGFR | 76.5 ± 15.7 | 75.1 ± 16.6 | 74.3 ± 15.2 | 71.7 ± 16.0 |
| Hypertension, n (%) | 853 (49.9) | 857 (50.1) | 864 (48.3) | 924 (51.7) |
| Any hypertension medication, n (%) | 514 (50.3) | 507 (49.7) | 546 (46.9) | 618 (53.1) |
| ACE Inhibitor, n (%) | 195 (47.6) | 215 (52.4) | 183 (50.8) | 177 (49.2) |
| Angiotensin II receptor blockers, n (%) | 66 (54.1) | 56 (45.9) | 91 (48.7) | 96 (51.3) |
| Alpha blocker use, n (%) | 133 (60.2) | 88 (39.8) | 9 (50.0) | 9 (50.0) |
| Beta blocker use, n (%) | 126 (51.2) | 120 (48.8) | 136 (45.0) | 166 (55.0) |
| Any lipid lowering medication, n (%) | 239 (51.7) | 223 (48.3) | 241 (47.2) | 270 (52.8) |
| Current aspirin use, n (%) | 393 (49.5) | 401 (50.5) | 305 (45.9) | 359 (54.1) |
| Smoking history, n (%) | ||||
| Never | 558 (49.6) | 567 (50.4) | 938 (52.8) | 838 (47.2) |
| Former | 654 (52.4) | 594 (47.6) | 390 (43.8) | 500 (56.2) |
| Current | 186 (47.2) | 208 (52.8) | 176 (52.9) | 157 (47.1) |
| Alcohol history, n (%) | ||||
| Never | 156 (55.5) | 125 (44.5) | 516 (57.1) | 387 (42.9) |
| Former | 459 (60.3) | 302 (39.7) | 349 (54.5) | 291 (45.5) |
| Current | 775 (45.2) | 940 (54.8) | 631 (43.8) | 811 (56.2) |
| Poor diet | 883 (49.7) | 892 (50.3) | 746 (48.7) | 786 (51.3) |
| Physical activity, MET-minutes/week | 4215.0 [2055.0, 8287.5] | 4537.5 [2160.0, 8460.0] | 3420.0 [1616.2, 6465.0] | 3888.8 [1920.0, 6810.0] |